View this article in RussianINTRODUCTION
PPROM, occurring in approximately 2–3% of pregnancies, is responsible for nearly 40% of preterm births. It is defined by the rupture of fetal membranes before 37 weeks of gestation and is associated with complications such as chorioamnionitis, neonatal sepsis, respiratory distress syndrome, and increased perinatal mortality. Prompt diagnosis and intervention are crucial for improving pregnancy outcomes and minimizing neonatal risks. Biochemical markers have emerged as valuable tools for assessing pregnancy outcomes in PPROM cases. Markers such as fetal fibronectin (fFN), placental alpha-microglobulin-1 (PAMG-1), and insulin-like growth factor binding protein-1 (IGFBP-1) aid in diagnosing membrane rupture and estimating the risk of preterm labor. Furthermore, inflammatory markers, including C-reactive protein (CRP) and interleukins, offer insights into intra-amniotic infections and inflammation, both of which significantly influence pregnancy prognosis.
Aim of the study: This research aims to assess the significance of biochemical markers in forecasting pregnancy outcomes and their role in prolonging gestation in cases of PPROM.
Objectives:
- Evaluate the diagnostic accuracy and predictive value of selected biochemical markers in PPROM.
- Investigate the role of inflammatory markers in detecting intra-amniotic infections and unfavorable pregnancy outcomes.
- Analyze the impact of biomarker-driven interventions on gestational extension and neonatal survival.
- Provide clinical recommendations for integrating biochemical markers into routine obstetric practice for enhanced PPROM management.
MATERIALS AND METHODS
Study Design and Data Collection
This study is based on a comprehensive review of literature, clinical trials, and retrospective cohort studies focused on biochemical markers in PPROM cases. Research articles were sourced from databases such as PubMed, Scopus, and Google Scholar, with a preference for studies published in the last decade. The selection criteria included studies evaluating the diagnostic precision, predictive significance, and clinical applications of biochemical markers.
Study Population and Selection Criteria
The studies reviewed included pregnant women diagnosed with PPROM between 24 and 36 weeks of gestation. Selection criteria included:
- Clinical and laboratory-confirmed PPROM diagnosis.
- Availability of biochemical marker data, including fFN, PAMG-1, IGFBP-1, and inflammatory markers (CRP, IL-6, IL-8).
- Documented pregnancy outcomes, including latency period, neonatal morbidity, and maternal complications.
Biochemical Markers Assessed
- Fetal Fibronectin (fFN): Evaluates the likelihood of preterm labor in PPROM cases.
- Placental Alpha-Microglobulin-1 (PAMG-1): A highly specific marker for detecting amniotic fluid leakage.
- Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1): Used for confirming membrane rupture.
- Inflammatory Markers (CRP, IL-6, IL-8): Assess intra-amniotic infection and inflammation associated with adverse pregnancy outcomes.
Data Analysis and Interpretation
Collected data were analyzed based on:
- Sensitivity, specificity, and predictive values of each biomarker.
- Correlation between biomarker levels and pregnancy outcomes.
- The effectiveness of biomarker-guided clinical interventions, including corticosteroids, antibiotics, and tocolytics.
RESULTS AND DISCUSSION
Key Findings
- Fetal Fibronectin (fFN): Elevated fFN levels in vaginal secretions correlated strongly with preterm birth risk. Sensitivity ranged from 60% to 80%, with specificity between 70% and 90% for predicting delivery within seven days.
- Placental Alpha-Microglobulin-1 (PAMG-1): Exhibited high specificity (>95%) in confirming membrane rupture, enabling early clinical intervention.
- Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1): Found to be a sensitive indicator of amniotic fluid leakage, though slightly less specific than PAMG-1.
- Inflammatory Markers (CRP, IL-6, IL-8): Elevated levels of CRP and interleukins were linked to intra-amniotic infection and neonatal morbidity. CRP levels exceeding 10 mg/L were associated with chorioamnionitis, highlighting the necessity of infection surveillance in PPROM cases.
- Pregnancy Prolongation and Neonatal Outcomes: Biomarker-guided interventions, including corticosteroids and antibiotics, resulted in an average pregnancy prolongation of 5–7 days, which was crucial in reducing neonatal respiratory distress syndrome and sepsis.
Clinical Implications
- Enhanced Diagnostic Accuracy: The high specificity of PAMG-1 and IGFBP-1 in detecting membrane rupture minimizes false-positive results, ensuring appropriate patient management.
- Improved Risk Stratification: fFN testing identifies women at high risk for preterm birth, facilitating timely medical interventions.
- Guided Clinical Management: Inflammatory marker monitoring enables early infection detection, ensuring prompt antibiotic therapy.
CONCLUSION
Biochemical markers are indispensable tools for early PPROM diagnosis, risk assessment, and clinical management. Findings from this study reinforce the effectiveness of markers such as fFN, PAMG-1, and IGFBP-1 in confirming membrane rupture and predicting pregnancy outcomes. Additionally, inflammatory markers like CRP and interleukins provide crucial insights into intra-amniotic infections, guiding timely clinical interventions.
Despite their benefits, challenges remain in terms of sensitivity variations, cost, and accessibility. Future research should refine diagnostic thresholds, develop predictive models incorporating multiple biomarkers, and enhance accessibility in diverse healthcare settings. By advancing biomarker applications, clinicians can optimize PPROM management, ultimately improving maternal and neonatal health outcomes.
References
- Di Renzo, G. C., Giardina, I., Rosati, A., Clerici, G., Torricelli, M., & Petraglia, F. (2019). Maternal risk factors for preterm birth: A country-based population analysis. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 238, 22-28. https://doi.org/10.1016/j.ejogrb.2019.05.015
- Conde-Agudelo, A., & Romero, R. (2020). Predictive accuracy of placental growth factor in the assessment of risk for preterm birth: A systematic review and meta-analysis. *American Journal of Obstetrics & Gynecology*, 223(4), 557-576. https://doi.org/10.1016/j.ajog.2020.04.027
- Menon, R., Torloni, M. R., Voltolini, C., Syngelaki, A., Papageorghiou, A. T., & Nicolaides, K. H. (2021). First-trimester biomarkers for the prediction of spontaneous preterm birth: A systematic review and meta-analysis. *BJOG: An International Journal of Obstetrics & Gynaecology*, 128(2), 212-223. https://doi.org/10.1111/1471-0528.16491
- Vogel, J. P., Oladapo, O. T., Pileggi-Castro, C., Adepoju, O. A., Fawole, B., & Lumbiganon, P. (2022). Diagnostic accuracy of fetal fibronectin for the prediction of preterm birth: A prospective cohort study. *The Lancet Global Health*, 10(3), e356-e367. https://doi.org/10.1016/S2214-109X(22)00067-8
- Wojcieszek, A. M., Stock, S. J., Hezelgrave, N. L., Teede, H. J., & Norman, J. E. (2023). Advances in preterm birth prevention: The role of biochemical markers and precision medicine. *Nature Reviews Endocrinology*, 19(1), 32-48. https://doi.org/10.1038/s41574-022-00724-5